fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2009-12-07 I Launch Merrion Pharmaceuticals (USA) Novo Nordisk (Denmark) oral insulin analogue (NN1952) type 1 and type 2 diabetes Germany See details
2009-12-07 III Result Gentium (Italy)   Defibrotide hepatic veno-occlusive disease in recipients of stem cell transplants.   See details
2009-12-06 III Result   Bayer HealthCare (Germany) Rivaroxaban venous thromboembolism   See details
2009-12-04 I Result Endotis Pharma (France)   EP42675 extracorporeal circulation in cardiac surgery, percutaneous coronary intervention in acute coronary syndromes   See details
2009-12-04 II Result BiogenIdec (USA) Roche (Switerland) ocrelizumab (humanised monoclonal antibody that selectively binds to CD20 antigen) relapsing-remitting multiple sclerosis (RRMS)   See details
2009-12-03 IIb Launch Oxagen (UK)   OC000459 (oral CRTH2 (DP2) antagonist) The G-protein coupled receptor, CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells also known as DP2) mediates allergic responses by interaction with the mast cell product prostaglandin D2. asthma   See details
2009-12-03 III Result   Roche (Switzerland) taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights diabetes   See details
2009-12-01 II Result Agennix (Germany)   talactoferrin severe sepsis USA See details
2009-11-30 III Launch   Bayer HealthCare (Germany) florbetaben PET Tracer Alzheimer's disease worldvide study on four different continents See details
2009-11-27 II Launch   Lundbeck (Denmark) Lu AE58054 (5-HT6-receptor antagonist) moderate Alzheimer's disease   See details
2009-11-27 II Result Biovitrum (Sweden)   Kiobrina® (recombinant human bile-salt-stimulated lipase - rhBSSL) enzyme replacement therapy to improve growth and development in preterm infants receiving pasteurized breast milk and/or formula   See details
2009-11-25 I Launch Glycotope (Germany)   GT-MAB 2.5-GEX® (monoclonal antibody directed against a novel tumor-specific combined carbohydrate-protein epitope present in a large number of patients of various cancers) Its fully human glycosylation was achieved by Glycotope´s proprietary technology platform GlycoExpress®, a screening and high yield production system of glycoengineered human cell-lines that allows significant enhancement of therapeutic potency by optimizing a protein’s glycosylation in various aspects. cancers Germany, Italy See details
2009-11-25 II Launch Ipsen (France)   BN83495 (first-in-class steroid sulfatase (STS) inhibitor) This compound is currently in further clinical development for postmenopausal metastatic breast cancer as well as in PI/II clinical development for castrate resistant prostate cancer. Ipsen plans to expand the clinical program to include ovarian cancers in the near future. advanced endometrial cancer   See details
2009-11-25 IIa Launch vasopharm (Germany)   VAS203 (NO-synthase inhibitor) traumatic brain injury Europe See details
2009-11-23 III Result Biotec Pharmacon (Norway)   soluble beta-glucan (SBG) diabetic foot ulcers   See details
[<<]      «      6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16      »      [57]